Samuel Singer, MD, FACS -- Chief, Gastric and Mixed Tumor Service

Samuel Singer, MD, FACS

Surgical Oncologist

Titles

Chief, Gastric and Mixed Tumor Service; Vincent Astor Chair of Clinical Research

Clinical Expertise

Soft Tissue Sarcomas; Gastrointestinal Stromal Tumor; Malignant Peripheral Nerve Sheath Tumor; Desmoid Tumor

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Singer accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 9/1/23)

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO

First Health

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Medicare Part A&B (traditional Medicare)

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Harvard University

Residencies

General Surgery - Brigham and Women's Hospital

Fellowships

Oncology - Francis Bitter National Magnet Laboratory

Board Certifications

Surgery

I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors.

Read more

I also have special expertise and experience in multimodality treatment, in which carefully planned surgery is combined, when appropriate, with radiation, chemotherapy, or targeted therapy.

I lead the Soft Tissue Sarcoma Disease Management Team at Memorial Sloan Kettering, which is a multidisciplinary group of soft tissue pathologists, medical oncologists, and radiation oncologists who work closely together to provide the best treatment plan for each individual patient.

A challenge in treating soft tissue sarcomas is that there are more than 50 subtypes, each of which is relatively uncommon. Patients’ outcomes are generally substantially better when they are managed by the sort of multidisciplinary team of experts that we can provide, in a center of excellence that treats many people with sarcoma. Our team of soft tissue sarcoma experts likely has the most extensive experience with these tumors of any medical group in the world.

In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.

The immediate goal of our research is to increase our understanding of sarcoma biology by discovering the alterations in DNA and RNA that cause sarcomas to develop and progress. These findings allow us to improve both the accuracy of diagnosis and the accuracy of predicting treatment outcome and survival for individual patients. These better predictions, in turn, will make it possible for patients to be given the treatment (such as a specific targeted therapy, chemotherapy, or radiation) most likely to be effective for their particular tumor.

Another goal of the research is to find new targeted therapies aimed specifically at alterations in particular tumor types. Examples of targeted therapies that I have been actively involved in developing and designing include anti-angiogenesis therapy for soft tissue sarcoma, imatinib (Gleevec®) for gastrointestinal stromal sarcoma, and cell cycle kinase inhibitor therapies (CDK4, AURKA, and PLK1), demethylating agents, HDAC inhibitors, and PPAR gamma ligands for various liposarcomas.

I am optimistic that this research will ultimately improve survival and quality of life for patients with soft tissue sarcoma.

Awards and Honors

  • Castle Connolly: America's Top Doctors (2023)
  • Castle Connolly: New York Magazine Top Doctors (2003-2010, 2019-2020)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Gastric and Mixed Tumor Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. Singer's Lab

Publications on PubMed

Visit PubMed for a full listing of Dr. Singer’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Samuel Singer discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures